How, When, and For Whom Should We Perform Therapeutic Drug Monitoring?
暂无分享,去创建一个
[1] D. Franchimont,et al. Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response , 2021, GastroHep.
[2] S. Vermeire,et al. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] B. Weiss,et al. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn's Disease Compared with Reactive Monitoring. , 2019, Gastroenterology.
[4] N. Mostafavi,et al. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. , 2019, Gastroenterology.
[5] S. Vermeire,et al. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. , 2019, Journal of Crohn's & colitis.
[6] G. Kaplan,et al. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[7] W. Sandborn,et al. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[8] S. Vermeire,et al. Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates. , 2019, Journal of Crohn's & colitis.
[9] J. Lambert,et al. Clinical response correlates with 4‐week postinjection ustekinumab concentrations in patients with moderate‐to‐severe psoriasis† , 2019, The British journal of dermatology.
[10] A. Gonçalves,et al. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease. , 2019, Inflammatory bowel diseases.
[11] E. Laserna-Mendieta,et al. Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits , 2019, Clinical chemistry and laboratory medicine.
[12] M. Parkes,et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. , 2019, The lancet. Gastroenterology & hepatology.
[13] P. Bossuyt,et al. Tu1818 – Ultra-Proactive Therapeutic Drug Monitoring Incorporating Infliximab Point-Of-Care Testing with Ad Hoc Dose Adjustment Reduces C-Reactive Protein Levels in Patients with IBD During Infliximab Maintenance Treatment , 2019, Gastroenterology.
[14] Marien González-Lorenzo,et al. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta‐analysis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] B. Flourié,et al. Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[16] D. Mould,et al. DOP56 Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial , 2019, Journal of Crohn's and Colitis.
[17] B. Vaughn,et al. Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease. , 2019, Journal of Crohn's & colitis.
[18] M. Gastonguay,et al. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation , 2019, Alimentary pharmacology & therapeutics.
[19] C. Brochard,et al. Predictors of relapse following infliximab de‐escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring , 2019, Alimentary pharmacology & therapeutics.
[20] A. Cheifetz,et al. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease. , 2018, Inflammatory bowel diseases.
[21] Yow-Ming C Wang,et al. Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm? , 2018, The AAPS Journal.
[22] S. Vermeire,et al. Influence of early adalimumab serum levels on immunogenicity and long‐term outcome of anti‐TNF naive Crohn's disease patients: the usefulness of rapid testing , 2018, Alimentary pharmacology & therapeutics.
[23] Ravy K. Vajravelu,et al. Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease , 2018, Journal of Crohn's & colitis.
[24] X. Roblin,et al. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD , 2018, Digestive Diseases and Sciences.
[25] D. Mould,et al. Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System , 2018, Journal of clinical pharmacology.
[26] R. Eliakim,et al. Prospective Observational Evaluation of Time‐Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study , 2018, The American Journal of Gastroenterology.
[27] R. Boshuizen,et al. Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra® microsampler vs dried blood spot. , 2018, Bioanalysis.
[28] S. Hanauer,et al. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. , 2018, Gastroenterology.
[29] M. Dubinsky,et al. Mo1838 - Pharmacokinetic Dashboard-Driven Infliximab Dosing in IBD:A Prospective Interventional Study , 2018 .
[30] D. Franchimont,et al. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. , 2018, Gastroenterology.
[31] L. Peyrin-Biroulet,et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study , 2018, Alimentary pharmacology & therapeutics.
[32] M. Dubinsky,et al. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? , 2018, Gastroenterology.
[33] R. Eliakim,et al. Early drug and anti‐infliximab antibody levels for prediction of primary nonresponse to infliximab therapy , 2018, Alimentary pharmacology & therapeutics.
[34] S. Vermeire,et al. Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease , 2017, Alimentary pharmacology & therapeutics.
[35] K. Farkas,et al. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort , 2017, Inflammatory bowel diseases.
[36] J. Andrews,et al. Review article: consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases , 2017, Alimentary pharmacology & therapeutics.
[37] A. Gils,et al. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases , 2017, Clinical pharmacology : advances and applications.
[38] Ravy K. Vajravelu,et al. Improved Long‐term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[39] T. Matsui,et al. Significance of measurement of serum trough level and anti‐drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial , 2017, Alimentary pharmacology & therapeutics.
[40] Siddharth Singh,et al. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. , 2017, Gastroenterology.
[41] B. Ryan,et al. Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center , 2017, JGH open : an open access journal of gastroenterology and hepatology.
[42] Siddharth Singh,et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. , 2017, Gastroenterology.
[43] A. Gonçalves,et al. Clinical performance of an infliximab rapid quantification assay , 2017, Therapeutic advances in gastroenterology.
[44] S. Vermeire,et al. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial , 2017, Gut.
[45] M. Abreu,et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease , 2017, Alimentary pharmacology & therapeutics.
[46] S. Vermeire,et al. Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation , 2016, Clinical and translational gastroenterology.
[47] K. Farkas,et al. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. , 2016, Journal of Crohn's & colitis.
[48] A. Gonçalves,et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays , 2016, Alimentary pharmacology & therapeutics.
[49] P. Rutgeerts,et al. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies , 2016, Journal of Crohn's & colitis.
[50] S. Vermeire,et al. Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. , 2016, Journal of pharmaceutical and biomedical analysis.
[51] R. Baldassano,et al. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease , 2016, Inflammatory bowel diseases.
[52] P. Rutgeerts,et al. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[53] S. Vermeire,et al. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples , 2016, Inflammatory bowel diseases.
[54] S. Marshall,et al. Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation , 2016, CPT: pharmacometrics & systems pharmacology.
[55] C. Ponsioen,et al. Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[56] S. Vermeire,et al. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases , 2015, Inflammatory bowel diseases.
[57] Els Brouwers,et al. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays , 2015, Therapeutic drug monitoring.
[58] H. Ogata,et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis , 2015, Journal of Gastroenterology.
[59] K. Van Steen,et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.
[60] S. Wicha,et al. TDMx: a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine. , 2015, International journal of antimicrobial agents.
[61] P. Rutgeerts,et al. Factors associated with short- and long-term outcomes of therapy for Crohn's disease. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[62] P. Rutgeerts,et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. , 2014, Gastroenterology.
[63] W. Sandborn,et al. Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study , 2014, Inflammatory bowel diseases.
[64] Els Brouwers,et al. Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization , 2014, Therapeutic drug monitoring.
[65] O. Dewit,et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[66] P. Rutgeerts,et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial , 2014, Gut.
[67] L. A. Christensen,et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial , 2013, Gut.
[68] H. Tanke,et al. A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study , 2013, Analytical and Bioanalytical Chemistry.
[69] Edgar Ramiterre,et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study , 2013, Annals of the rheumatic diseases.
[70] Sergio Gutierrez-Ureña,et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study , 2013, Annals of the rheumatic diseases.
[71] L. Peyrin-Biroulet,et al. Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study , 2013, Inflammatory bowel diseases.
[72] R. Eliakim,et al. Clinical utility of antihuman lambda chain‐based enzyme‐linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti‐infliximab antibodies , 2012, Inflammatory bowel diseases.
[73] Michael G Tovey,et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. , 2011, Journal of immunological methods.
[74] R. Gearry,et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease , 2011, Inflammatory bowel diseases.
[75] M. Dubinsky,et al. A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine , 2005, The American Journal of Gastroenterology.
[76] P. Rutgeerts,et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. , 2003, Gastroenterology.
[77] L. Denson,et al. Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients. , 2019, Journal of pediatric gastroenterology and nutrition.
[78] S. Vermeire,et al. Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information , 2018, The AAPS Journal.
[79] M. Dubinsky,et al. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients , 2016, The AAPS Journal.
[80] R. Eliakim,et al. Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease. , 2016, Journal of Crohn's & colitis.
[81] T. Buclin,et al. Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools , 2012, Clinical Pharmacokinetics.